Fig. 5

Neoepitope-targeted complement inhibition with B4-Crry improves functional outcome after SCI. a Assessment of locomotor activity over a 21-day period post-SCI using the 10-point BMS scale. A score of 9 represents no impairment of locomotor activity. Groups consisted of untreated injured WT C57bl/6 mice and B4-Crry-treated mice. Mean ± SE, *p < 0.001, n = 6–8. b Grip Walk test performed at 21 days post-SCI. Groups as above. Mean ± SE, *p < 0.05, n = 6–8